Abstract:In the past decades, reconstituted high density lipoprotein (rHDL) has been successfully developed as a drug carrier since the enhanced HDL-lipids uptake is demonstrated in several human cancers. In this paper, rHDL, for the first time, was utilized to co-encapsulate two hydrophobic drugs: an anticancer drug, paclitaxel (PTX), and a new reversal agent for P-gp (P-glycoprotein)-mediated multidrug resistance (MDR) of cancer, N-cyano-1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-N′-octyl-2(1H)-isoquinoline-carboximidamide (HZ08). We proposed this drug co-delivery strategy to reverse PTX resistance. The study aimed to develop a biomimetic nanovector, reconstituted high density lipoprotein (rHDL), mediating targeted PTX-HZ08 delivery for cancer therapy. Using sodium cholate dialysis method, we successfully formulated dual-agent co-delivering rHDL nanoparticles (PTX-HZ08-rHDL NPs) with a typical spherical morphology, well-distributed size (~100nm), high drug encapsulation efficiency (approximately 90%), sustained drug release properties and exceptional stability even after storage for 1month or incubation in 10% fetal bovine serum (FBS) DMEM for up to 2days. Results demonstrated that PTX-HZ08-rHDL NPs significantly enhanced anticancer efficacy in vitro, including higher cytotoxicity and better ability to induce cell apoptosis against both PTX-sensitive and -resistant MCF-7 human breast cancer cell lines (MCF-7 and MCF-7/PTX cells). Mechanism studies demonstrated that these improvements could be correlated with increased cellular uptake of PTX mediated by scavenger receptor class B type I (SR-BI) as well as prolonged intracellular retention of PTX due to the HZ08 mediated drug-efflux inhibition. In addition, in vivo investigation showed that the PTX-HZ08-rHDL NPs were substantially safer, have higher tumor-targeted capacity and have stronger antitumor activity than the corresponding dosage of paclitaxel injection. These findings suggested that rHDL NPs could be an ideal tumor-targeted nanovector for simultaneous transfer of insoluble anticancer drug and drug resistance reversal agents. The PTX-HZ08-rHDL NPs co-delivery system might be a new promising strategy to overcome tumor drug resistance.

Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Ratiometric Co-Encapsulation and Co-Delivery of Doxorubicin and Paclitaxel by Tumor-Targeted Lipodisks for Combination Therapy of Breast Cancer

Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer

Ratiometric Co-Delivery of Doxorubicin and Docetaxel by Covalently Conjugating with Mpeg-Poly(β-malic Acid) for Enhanced Synergistic Breast Tumor Therapy

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Natural Particulates Inspired Specific-Targeted Codelivery of Sirna and Paclitaxel for Collaborative Antitumor Therapy

Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.

Reconstituted High Density Lipoprotein Mediated Targeted Co-Delivery of HZ08 and Paclitaxel Enhances the Efficacy of Paclitaxel in Multidrug-Resistant MCF-7 Breast Cancer Cells.

Synergistic Breast Tumor Cell Killing Achieved by Intracellular Co-Delivery of Doxorubicin and Disulfiram Via Core-Shell-corona Nanoparticles

Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation.

Palmitoyl Ascorbate and Doxorubicin Co-Encapsulated Liposome for Synergistic Anticancer Therapy.

Efficient Co-delivery of Doxorubicin and Methotrexate by Ph-Sensitive Dual-Functional Nanomicelles for Enhanced Synergistic Antitumor Efficacy

Dendrimer-based Multilayer Nanocarrier for Potential Synergistic Paclitaxel–doxorubicin Combination Drug Delivery

Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells

Hyaluronic Acid Modified Liposomes for Targeted Delivery of Doxorubicin and Paclitaxel to CD44 Overexpressing Tumor Cells with Improved Dual-Drugs Synergistic Effect

Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.

Co-delivery systems of paclitaxel prodrug for targeted synergistic therapy of breast cancer

Doxorubicin/cisplatin Co-Loaded Hyaluronic Acid/chitosan-Based Nanoparticles for in Vitro Synergistic Combination Chemotherapy of Breast Cancer

Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation

Combination Chemotherapy Of Doxorubicin, All-Trans Retinoic Acid And Low Molecular Weight Heparin Based On Self-Assembled Multi-Functional Polymeric Nanoparticles